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Cell-mediated immunity and natural killer (NK) activity play an
important role in immunosurveillance in neoplasia (Burnet, 1971;
Broder and Negson, 1982). Recent studies suggested interesting
relationships between decreased natural cytotoxicity and tumour
spread (Robertson and Ritz, 1990). NK activity is significantly
decreased in advanced cervical carcinoma compared with early
stage (Garzetti et al, 1996) and associated with an impairment of
interleukin 2 (IL-2) production (Rani et al, 1992), representing a
risk factor for the progression of neoplasia (Shiffman and Brinton,
1995). IL-2 is required for NK activity (Henny et al, 1981), and
both may be also thymus controlled (Goldstein, 1984). Some
models of cancer (Mocchegiani et al, 1990, 1994) show reduced
plasma levels of active thymulin, the zinc-bound biologically
active form (Zn-FTS) of the ‘facteur timique serique’ (FTS)
(Dardenne et al, 1982). Peripheral low zinc bioavailability has been
proposed as one of the mechanisms involved in cancer-related
thymic immune deficiency (Fabris and Mocchegiani, 1995). Zinc is
necessary for normal cell-mediated immunity (Chandra, 1985).
However, the involvement of zinc deficiency in neoplasia remains
unknown (Garofalo et al, 1979; Gorodetsky et al 1985; Fabris and
Mocchegiani, 1995). Zinc is bound to various metalloproteins and
other macromolecules produced by neoplastic cells (Bremner and
May, 1989). Normal levels of zinc in neoplastic diseases are often
associated with low peripheral zinc bioavailability (Fabris and
Mocchegiani, 1995) because zinc tends to bind to proteins with a
higher zinc binding affinity (Kd) than thymulin (10–7 M) (Gastinel et
al, 1984). In this context, a2-macroglobulin may play a key role for
two reasons: firstly, because of a high Kd for zinc (10–10 M) (Giroux,
1975) and, secondly, because a2-macroglobulin is implicated as an
inhibitor of matrix metalloproteases (MMPs) (Enghild et al, 1989)
against invasive tumour proliferation (Stetler-Stevenson et al,
1993). Indeed, increases in a2-macroglobulin have been reported in
experimental neoplasia (Mackiewicz et al, 1993) and in melanoma
patients (Matoska et al, 1988). Therefore, we measured plasma
levels of zinc, of active thymulin (Zn-FTS) and of a2-macroglob-
ulin in patients affected by locally advanced cervical carcinoma.
Because the non-zinc-bound form of thymulin (FTS) is inactive,
and can be unmasked by in vitro zinc addition to plasma samples
containing the total amount of thymulin (active Zn-FTS+inactive
FTS) produced (Mocchegiani et al, 1994), we also tested total
thymulin. NK activity and IL-2 plasma levels were measured, as
well as plasma soluble IL-2 receptor (sIL-2R), because of its
negative influence on IL-2 availability in solid tumours (Rubin
et al, 1986; Pavlidis et al, 1995). In vitro zinc studies on IL-2
production from peripheral blood mononuclear cells (PBMCs) of
cancer patients were carried out in view of a possible clinical trial
with zinc.
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Summary Decreased natural killer (NK) activity as well as interleukin 2 (IL-2) are risk factors for the progression of cervical carcinoma. NK
activity and IL-2 may be thymus controlled. Plasma levels of active thymulin, a zinc-dependent thymic hormone (ZnFTS), are reduced in
cancer because of the low peripheral zinc bioavailability. Zinc and thymulin are relevant for normal immune functions. a2-Macroglobulin is an
inhibitor of matrix metalloproteases (MMPs) against invasive tumour proliferation. Because a2-macroglobulin has a binding affinity (Kd) for
zinc that is higher than does thymulin, it may play a key role in immune efficiency in cancer. Plasma samples of 22 patients (age range 35–60
years) with locally advanced squamous cervical carcinoma and with FIGO stage Ib2–IIb were examined. They showed reduced active
thymulin, decreased NK activity and IL-2 production, increased soluble IL-2 receptor (sIL-2R) and augmented a2-macroglobulin in the
circulation, whereas plasma zinc levels were within the normal range for age. Significant positive correlations were found between zinc or
active thymulin and a2-macroglobulin (r = 0.75, P < 0.01, r = 0.78, P < 0.01, respectively) in cancer patients. In vitro zinc increases IL-2
production from peripheral blood mononuclear cells (PBMCs) of cancer patients. These data suggest that an increase in a2-macroglobulin,
which competes with thymulin for zinc binding, may be involved in causing a thymulin deficit with a consequent decrease of IL-2 and NK
cytotoxicity. Thus, physiological zinc treatment in cervical carcinoma maybe restores impaired central and peripheral immune efficiency.
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PATIENTS AND METHODS
Patients
Blood samples were drawn from 22 patients with locally advanced
squamous cervical carcinoma after radical surgery but with no
previous treatment with antiblastic drugs. They were recruited
from our series of cervical carcinoma patients at the Institute of
Gynaecology and Obstetrics, Ancona University, Italy, from
January 1994 to December 1995. Other inclusion criteria were:
age ≤60 years; stage Ib2–IIb disease according to the FIGO
classification (International Federation of Gynaecology and
Obstetrics) (Grigsby 1996). Exclusion criteria were: present or
past smoking; previous radiotherapy and/or chemotherapy;
immunological diseases, including HIV seropositivity; immuno-
suppressive treatment in the last 4 months before the present study.
Twelve outpatients age matched and with the same socio-
economic status, with normal cervical Pap smear and without
immune or neoplastic diseases were used as healthy controls. All
tests were performed with informed consent from patients and
healthy control subjects.
Thymulin determination
Plasma zinc-bound active thymulin (Zn-FTS), as extensively
described elsewhere (Bach et al, 1975; Mocchegiani et al, 1994),
was measured using a bioassay based on the ability to restore the
inhibitory effect of azathioprine on rosette formation in spleen
cells (RFCs) from young thymectomized mice. Results are
expressed as log–2 of the reciprocal maximal dilution of tested
plasma that induces this phenomenon (Bach et al, 1975). This
technique is specific for thymulin, because the assay is unaffected
by other thymic hormones, and the rosette-inducing activity is
removed completely by passing plasma samples through an
antithymulin immunoabsorbent (Bach et al, 1975). The sensitivity
of this bioassay allows for the detection of 1pg ml–1 synthetic
thymulin (Sigma, USA). Because in two consecutive blind assays
no difference of more than one log–2 was found in all samples, the
assay was considered reliable (Bach et al, 1975). This bioassay is
still required because questions have been raised over the speci-
ficity of the radioimmunoassays (RIAs) developed up to now
(Mocchegiani et al, 1994). To avoid possible interference due to
zinc turnover, the thymulin bioassay was performed with zinc-
enriched medium by in vitro addition of zinc sulphate at a final
concentration of 200nM, which has been shown to be the optimal
concentration for unmasking inactive zinc-unbound thymulin
(FTS) molecules and showing the total amount of thymulin
produced (active Zn-FTS+inactive FTS) (Mocchegiani et al,
1994). The apparently low molar concentration of zinc required
may be explained by the fact that the bioavailable free zinc is no
more than 2–3% of total plasma zinc, the major quota being bound
to proteins which are retained by membranes with a 50000 mole-
cular weight cut-off (Mocchegiani et al, 1994).
Zinc and a2-macroglobulin plasma levels
Plasma zinc was measured using the method of Fernandez and
Khan (1971). Blood samples were collected directly into fluori-
nated tubes (no. 115317, LP, Italy) in order to avoid possible con-
tamination, and centrifuged 20min later at 3000gfor 10min.
Plasma samples were frozen at –70°C and stored until used.
Plasma zinc levels were determined by atomic absorption
spectrophotometry (AAS) against zinc reference standards
(Mocchegiani et al, 1994). The data were expressed in mg dl–1.
Plasma a2-macroglobulin levels were tested using the nephelori-
metric method (Boheringer, Italy). The data are expressed in mg ml–1.
IL-2 plasma determination
Interleukin 2 (IL-2) was measured in plasma by means of an
enzyme-linked immunosorbent assay (Inter Test 2X Human IL-2
ELISA kit, Genzyme, USA) that is based on a sandwich principle
using a monoclonal antibody in conjunction with polyvalent anti-IL-
2 antibody. The results, expressed in pg ml–1, are the average of two
separate assays. The specificity of the determinations was confirmed
in all cases by blocking interleukin 2 (by 60% or more) with a rabbit
polyclonal antibody. The sensitivity of the Inter-test IL-2 kit ranged
(95% confidence limits) between 100 and 2500pg ml–1.
Soluble IL-2 receptor (sIL-2R) plasma determination
Plasma concentrations of sIL-2R were measured by means of an
ELISA commercial kit (Predicta IL-2R, Genzyme that is based on
the cleavage of IL-2R to yield sIL-2R using a biotinylated rabbit
anti-IL-2R antibody conjugate with a peroxidase enzyme. The
results, expressed in pg ml–1, are the average of two separate
assays and are referred to a standard curve. The sensitivity of the
Predicta ELISA kit ranged (95% confidence limits) between 350
and 4000pg ml–1.
NK cytotoxic assay
PBMCs were fractionated on Ficoll-Hipaque (Pharmacia, Sweden)
and separated by density gradient centrifugation (400g, 30min).
Cells from the interface of the gradient were washed with phos-
phate-buffered saline (PBS) (Ca2+ and Mg2+ free), resuspended in
RPMI-1640 (Gibco, Grand Island, NY, USA) plus 10% fetal calf
serum (FCS, Gibco), and incubated in plastic Petri dishes for 1h at
37°C in 5% carbon dioxide in air to remove adherent cells. The
lymphocytes were then washed with RPMI-1640, counted and
resuspended at a concentration of 2´106 ml–1 in RPMI-1640
containing 10% decomplemented FCS, penicillin (100U ml–1) and
streptomycin (100mg ml–1) (complete medium, CM). Viability was
always greater than 98% as determined by trypan blue exclusion.
The K562 tumour cell line, a myeloid cell line derived from a
pleural effusion of a patient with a chronic myelocyte leukaemia in
blast crisis, was used as the target cell. These cells were maintained
in continuous culture throughout the study.
Briefly, NK cell assay was performed by a fluorimetric method,
as extensively reported elsewhere (Provinciali et al, 1992), using a
stock solution of carboxyfluorescein diacetate (c’FDA, Molecular
Probes, OR, USA) (20mg ml–1 acetone, stored at –20°C) diluted
in phosphate-buffered saline (PBS) to give a final concentration of
75mg ml–1. K562 target cells were used at a concentration of 1 ´
105 ml–1. Effector target cell ratios from 20:1 to 2.5:1 were tested
in triplicate after 3h incubation at 37°C in a humidifier under 5%
carbon dioxide. The fluorescence in the supernatants was read
with a Titertek Fluoroskan II (Flow Laboratories, USA). The
percentage of specific lysis was calculated as follows:
Percentage of specific lysis = (Fmed – Fexp)/Fmed,
where Frepresents the fluorescence of the solubilized cells after
the supernatant has been removed, med is the fluorescence from
target incubated in medium alone, and exp is the fluorescence246 E Mocchegiani et al
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from target incubated with effector cells. The data were expressed
in lytic units (LU 20 per 106 cells).
In vitro cultures
Blood samples from adult healthy control subjects (five subjects)
and cancer patients (five subjects) were diluted 1:2 with PBS (Ca2+
and Mg2+ free, Gibco), fractionated with Ficoll-Hipaque
(Pharmacia, Sweden) and the PBMCs separated by density
gradient centrifugation at 18°C for 30min at 400 g. The PBMCs
were collected with a Pasteur pipette from the interface of the
gradient, washed twice with PBS, counted and resuspended at a
concentration of 1 ´106 cells ml–1 in RPMI-1640 (Gibco, USA)
containing penicillin (100U ml–1) and streptomycin (100mg ml–1)
and then put in culture. The culture (in triplicate) of PBMCs
without zinc or with zinc at the concentrations of 1mM(physiolog-
ical doses) (Dardenne et al, 1982; Mocchegiani et al, 1994) and 10
mM(up-physiological doses) (Dardenne et al, 1982; Mocchegiani
et al, 1994) were incubated in zinc-free RPMI-1640 medium at
37°C in a humidifier under 5% carbon dioxide for 24h. At the end
of the incubation, the viability of cells was evaluated by means of
trypan blue exclusion. The viability was greater than 98%. PBMCs
were then centrifuged for 10min at 400g. The supernatants
obtained were harvested and IL-2 production was tested in the
supernatants by means of Inter-test IL-2 ELISA kit (Genzyme).
The data were expressed in pg ml–1.
Statistical analysis
The significance between the means was assessed by paired
Student’s t-test and Anova (one way) test. The correlations were
determined by linear regression analysis by the least squares
method. Differences were considered significant when P< 0.05.
RESULTS
Clinicopathological characteristics of cancer patients
The median age of our patients was 51.5 years (range 35–60 years).
The median parity was 2 (range 1–4). Table 1 shows the clinico-
pathological characteristics of the patients. Eleven patients (50%)
were in stage Ib2, four patients were in stage IIa and seven patients
were in stage IIb of the neoplastic disease. Involvement of lymph-
nodes was observed in nine cases (41%) and lymphovascular inva-
sion was present in 13 cases (59%). In addition, 17 cancer patients
showed HPV DNA positivity. HPV DNA 16 is the most frequent
type (71%) [polymerase chain reaction (PCR) technique].
Plasma thymulin levels (active and total), plasma zinc
concentrations and plasma a2-macroglobulin levels in
cancer patients
Table 2 shows that active thymulin plasma levels (Zn-FTS) were
reduced in cancer patients compared with age-matched healthy
control subjects (P< 0.003). The total thymulin level (Zn-FTS +
FTS) was not affected by the tumour, values being similar to those
of healthy controls subjects (Table 2). Plasma zinc levels were in the
normal range for age of the cancer patients (Table 2). However,
some cancer patients, on an individual level, showed reduced
zincaemia compared with healthy control subjects (data not shown).
Significant increases in a2-macroglobulin plasma concentra-
tions are observed in cancer patients compared with healthy
control subjects (P< 0.001) (Table 2).
When plasma zinc levels from healthy control subjects and
cancer patients are plotted against the corresponding values of in
vitro thymulin saturable fraction (ratio total thymulin
ZnFTS+FTS/ active thymulin ZnFTS), a significant inverse cor-
relation is found (r= –0.60; P< 0.05) (Figure 1). When plasma
zinc levels or active thymulin concentrations from healthy control
subjects and cancer patients were plotted against the cor-
responding values of plasma a2-macroglobulin, significant posi-
tive correlations were also observed (r= 0.75, P< 0.01; r= 0.78,
P< 0.01, respectively).
Table 1Clinicopathological characteristics of cancer patients
Parameters No. cases Percentage
FIGO stage
IB2 11 50
IIA 4 18
IIB 7 32
Histological grade
G1  15 68
G2  2 9
G3  5 23
Lymphovascular space invasion
941
13 59
Lymph node metastases
13 59
941
HPV DNA positivity
523
17 77
Table 2Plasma active (Zn-FTS) and total (Zn-FTS+FTS) thymulin, zinc an d  a2-macroglobulin levels in cervical carcinoma patients
Healthy control subjects Cervical carcinoma
Active thymulin (ZnFTS) (log–2) 3.0 ±0.3 1.5 ±0.5**
Total thymulin (ZnFTS+FTS) (log–2) 4.5 ±0.3 4.5 ±0.3
Zinc (mg dl–1) 112.4 ±16.1 100.7 ±9.3
a2-Macroglobulin (mg dl–1) 178.8 ±17.2 260.0 ±72.8*
*P < 0.003 when compared with healthy age-matched control subjects. **P < 0.001 when compared with healthy age-matched control subjects.Zinc, thymulin and NK activity in cervical carcinoma 247
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Plasma IL-2 levels, plasma soluble IL-2 receptor (sIL-
2R) concentrations and natural killer (NK) activity in
cancer patients
Figure 2A and B shows that both NK activity and plasma IL-2
levels are reduced in cancer patients compared with healthy control
subjects (P < 0.05 and P < 0.01 respectively). Concomitantly,
significant increases of plasma sIL-2R concentrations were
observed in cancer patients compared with healthy controls (P <
0.01) (Figure 2C). When the data for IL-2 or sIL-2R from healthy
control subjects and cancer patients were plotted against the cor-
responding values of NK activity, significant positive or negative
correlations were found for IL-2 or sIL-2R (r = 0.78, P < 0.01; r =
–0.71, P < 0.01 respectively).
When the data for zinc and IL-2 from healthy control subjects
and cancer patients were plotted against the corresponding values
for NK activity, significant correlations were observed (r = 0.80, P
< 0.01; r = 0.78, P < 0.01, respectively), as well as between NK
activity and active thymulin or thymulin saturable fraction (r =
0.92, P < 0.01; r = 0.90, P < 0.01, respectively).
Effect of in vitro zinc addition on IL-2 production in the
supernatants from PBMCs of cancer patients
Table 3 shows IL-2 production in the supernatants from PBMCs of
cancer patients and healthy control subjects after in vitro zinc
addition [physiological (1 mM) or up-physiological (10 mM) dose].
Significant increases in IL-2 production are observed in the super-
natants from PBMCs of cancer patients after in vitro zinc addition
at a concentration of 1 mM compared with values without zinc (P <
0.001). However, it is noteworthy that more significant increases
in IL-2 production are present when zinc is added at 10 mM
compared with zinc at 1 mM (79.9 pg ml–1 vs. 50.6 pg ml–1 of IL-2)
(Table 3). When zinc (1 mM) was added to cultures of PBMCs
from healthy control subjects, no substantial modifications of IL-2
production were observed compared with PBMC cultures without
zinc (Table 3). IL-2 production was decreased in healthy controls
after in vitro zinc addition at 10 mM compared with those controls
without zinc or with zinc 1 mM (P < 0.01) (Table 3).
DISCUSSION
Active thymulin (Zn-FTS) was reduced in patients affected by
locally advanced cervical carcinoma, whereas total thymulin level
(active thymulin Zn-FTS+inactive thymulin FTS) was in the
normal range. Plasma zinc levels were within the normal range for
the age of the cancer patients, whereas a2-macroglobulin was
increased. NK activity as well as IL-2 production were reduced.
Concomitantly, sIL-2R was increased.
Cell-mediated immunity is decreased in neoplasia (Burnet,
1971; Broder and Negson, 1982). The causes are still unclear and
undefined (Dilman, 1977). We suggest that tumour-associated
Ratio (total thymulin/active thymulin)
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immunodeficiency may depend on changes in thymic endocrine
activity, which is necessary for good cell-mediated immunity
(Goldstein, 1984).
Although histological evidence of thymic abnormalities in
neoplasia is not currently available (Hamoudi et al, 1982), the
level of one of the best-known thymic hormones, i.e. thymulin, has
been found to be reduced in cancer (Mocchegiani et al, 1990,
1994). In agreement with these studies, a significant reduction in
active thymulin has also been observed in patients with locally
advanced cervical carcinoma. Low peripheral bioavailability of
zinc, which plays a pivotal role in normal immune function
(Chandra, 1985), may be involved. Indeed, zinc is required for the
biological activity of thymulin (Zn-FTS) (Dardenne et al, 1982),
whereas the non zinc-bound form (FTS) is inactive with an
inhibitory action on the active form (Zn-FTS) (Mocchegiani et al,
1994) probably competing with FTS receptors as do FTS
analogues (Pleau et al, 1979). In vitro addition of zinc to plasma
samples containing FTS is able to unmask the inactive form (FTS),
revealing the total amount of thymulin (active+inactive) in the
circulation (Mocchegiani et al, 1994). The ratio of total thymulin
to active thymulin is the thymulin fraction that is saturable by zinc
ions and represents a good marker of true zinc deficiency and,
consequently, of peripheral zinc which may be low in spite of
plasma zinc levels in the normal range (Fabris and Mocchegiani,
1995). This thymulin methodological procedure performed in
solid tumours and in leukamia has allowed us to demonstrate that
reduced plasma levels of active thymulin (Zn-FTs) are largely due
to the presence of non-zinc-bound inactive thymulin molecules
(FTS) not saturated by zinc ions despite zinc levels in the normal
range (Mocchegiani et al, 1990; Mocchegiani et al 1994).
Supplementary zinc restores the thymic endocrine defect (Fabris
and Mocchegiani, 1995).
Because atomic absorption spectrophotometry (AAS) measures
free and patients with bound zinc (Fernandes and Khan, 1971),
normal plasma zinc levels for the age are observed in patients with
cervical carcinoma. This fact is misleading because, when plasma
zinc is plotted against the saturable thymulin fraction, a significant
inverse correlation is found (Figure 1), suggesting low peripheral
zinc bioavailability results in saturation of non-zinc-bound
thymulin molecules produced in this type of cancer. Such an
assumption is supported because the fact that total thymulin does
not differ in cancer patients and healthy control subjects.
Such a phenomenon may occur because zinc is required for the
biological activity of many enzymes and metalloproteins, which
bind zinc with different binding affinities (Kd) (ranging from
10–10 M for a2-macroglobulin to 10–3 M for angiotensin-converting
enzyme) (Bremner and May, 1989). Thus, by the low peripheral
zinc bioavailability might occur because of increased concen-
trations of some zinc-binding proteins. In this context, 
a2-macroglobulin may play a crucial role for two reasons: first its
binding affinity (Kd for zinc (10-10 M) (Giroux, 1975), higher than
that of thymulin (10-7 M) (Gastinel et al, 1984); secondly, 
a2-macroglobulin is an inhibitor of matrix metalloproteases
(MMPs), which are involved in tumour cell proliferation (Stetler-
Stevenson et al, 1993); a direct interaction between MMPs and a2-
macroglobulin removes proteolytic potential from the circulation
(Enghild et al, 1989). This direct inhibitory role has been consid-
ered to be a reserve when other inhibitors [tissue inhibitors of
matrix metalloproteinases (TIMPs)] are deficient (Chu et al,
1994). MMPs are induced temporarily in response to exogenous
signals such as various cytokines produced by macrophages,
mainly IL-1, IL-6 and TNF (Kahari and Saarialho Kere, 1997),
which are increased in cancer (Dinarello, 1984). a2-macroglobulin
binds these cytokines (Chu et al, 1994) in order to induce latency
on cytokines (James, 1990). In vitro studies have shown that zinc
is required for this binding (Getting and Crews, 1994). a2-
macroglobulin thus exerts this indirect inhibitory action on MMPs
by means of the cytokine-binding inducing latency on cytokines
themselves, and consequently, minor MMPs production. This may
be one of the possible inhibitory mechanisms of a2-macroglobulin
against MMPs, as suggested by James (1990) and Chu et al (1994).
Thus, increased a2-macroglobulin levels are expected in cervical
carcinoma not as an epiphenomenon but as a cause or a conse-
quence of the tumour and, as such, a necessary protective biologi-
cal event. Moreover, this protective role of a2-macroglobulin may
further justify the shift of zinc towards this metalloprotein in
cervical carcinoma. On the other hand, increases in a2-macroglob-
ulin have been also found in tumour experimental models
(Mackiewicz et al, 1993) and in melanoma patients, although such
increments were associated with unfavourable prognosis (Matoska
et al, 1988). This is not surprising because the shift of zinc results
in a low zinc bioavailability with consequent reduction in periph-
eral thymulin molecules saturated by zinc ions, resulting in
reduced zinc-bound active thymulin and impairment of immune
efficiency against tumours. The existence of significant correla-
tions between zinc or active thymulin and a2-macroglobulin in
cancer patients may be in line with this interpretation; while posi-
tive correlation between plasma zinc and active thymulin (ZnFTS)
is obvious because many thymulin molecules are present in zinc-
unbound form (FTS) due to zinc sequestration by a2-macroglob-
ulin with consequent increments of this metalloprotein in cancer
patients (see Table II). Such a phenomenon occurs for metalloth-
ioneins in leukaemia characterized by normal zincaemia and
reduced levels of active thymulin (Mocchegiani et al, 1994).
Despite metallothioneins having been suggested as donors of zinc
for thymulin activation in thymic epithelial cells (TEC) (Savino et
al, 1984) such a donation does not occur in leukemia, and more in
general in cancer, because of the reactivation of thymulin after in
vitro zinc addition up to plasma samples (Mocchegiani et al,
1994). Indeed supplementing zinc corrects both thymic and
peripheral immune defects in cancer (Fabris and Mocchegiani,
1995). Thus, taking into account the role of thymulin (Goldstein,
1984) and zinc (Chandra, 1985) for cell-mediated immunity, the
reduced active thymulin levels may be relevant for the efficiency
of peripheral immune functions in cervical carcinoma, because the
major quota of zinc bound with a2-macroglobulin. Thereby, while
one hand increased a2-macroglobulin in cancer may be useful as
Table 3 Effect of in vitro zinc addition on IL-2 production from PBMCs of
cancer patients
Dose of zinc IL-2 production (pg ml–1)
Cervical carcinoma Without zinc 29.3 ± 8.7
Zinc 1 mM 50.6 ± 9.2*
Zinc 10 mM 79.9 ± 8.5*
Healthy control subjects Without Zinc 178.4 ± 6.5
Zinc 1 mM 178.4 ± 6.6
Zinc 10 mM 123.5 ± 8.5**
*P < 0.001 when compared with the values without zinc. **P < 0.01 when
compared with the values of healthy controls without zinc or zinc 1 mM.Zinc, thymulin and NK activity in cervical carcinoma 249
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protective agent, on the other hand it may be dangerous for
immune efficiency, as recently also suggested for increased
metallothioneins in ageing: from protective in young age to
dangerous role in old age for immune functions (Mocchegiani et
al, 1997).
Experimental evidence shows that zinc-bound active thymulin
(ZnFTS) affects both in vivo (Bardos and Bach, 1982) and in vitro
NK activity (Muzzioli et al, 1992), which is, in turn, under the
control of IL-2 (Henney et al, 1981). In addition, zinc affects IL-2
activity (Tanaka et al, 1990). Natural Killer (NK) activity and
cytotoxic-T cell response (CTLs) are important to test the cyto-
toxic functions (Bontkes et al, 1997). However a minority of CTLs
are activated in cervical carcinoma and the cytotoxic activity is
very low and so not explicative to really document cytotoxic func-
tion in cervical carcinoma (Park and Kim, 1989; Bontkes et al
1997). The Natural Killer activity seems a more reliable cytotoxic
test (Park and Kim, 1989; Bontkes et al, 1997).
Indeed, the relevance of NK activity to the clinical outcome of
patients with cervical carcinoma has been well documented
(Garzetti et al, 1995). In addition, decreased IL-2 production as a
risk factor for the progression of cervical carcinoma (Shiffman and
Brinton, 1995) has also been shown. In agreement with these
studies, NK activity and IL-2 production are both decreased in
cervical carcinoma. Such decreases are correlated with increases in
soluble IL-2 receptor (sIL-2R) in the circulation. Because sIL-2R
has a negative influence on the IL-2 availability in solid tumours
(Rubin et al, 1986; Pavlidis et al, 1995), this might explain the
reduced plasma IL-2 levels found in cancer patients, and it gives
further support to the importance of IL-2 and NK activity in
cervical carcinoma. Reduction in NK activity, low bioavailability
of IL-2 and increased circulating sIL-2R are present in some types
of cancer (Gooding et al, 1995; Wasik et al, 1996), characterized by
slight zinc deficiency (Fabris and Mocchegiani, 1995).
Thus, reduced IL-2, together with the knowledge that active
thymulin is also involved in IL-2 production (Goldstein, 1984) and
on NK activity (Bardos et al, 1982; Muzzioli et al, 1992), suggests
the crucial role played by zinc and thymulin for IL-2 and NK
activity in cervical carcinoma. The presence of significant correla-
tions between plasma zinc levels and plasma IL-2 concentrations
and between NK activity and plasma zinc levels or active thymulin
concentrations or the zinc-saturable thymulin fraction may support
this interpretation.
Intriguing points are also related to the role of zinc in the
extrathymic T-cell pathway (Mocchegiani et al, 1997), which is
important for NK-cell maturation in tumours (Seki et al, 1991).
Thus, good zinc bioavailability may be crucial for the effective-
ness of NK cells of thymic and extrathymic origin during cancer
development. Zinc is also required by macrophages for TNF-a
production (Driessen et al, 1994), which is, in turn, involved either
in NK activity (Ogata et al, 1995) or in apoptosis in tumour cell
lines through its transcriptional factor NF-kB (VanAntwerp et al,
1996). These findings, together with our data, suggest a possible
beneficial effect of zinc treatment on the efficiency of the entire
immune system in cervical carcinoma, as documented in other
types of cancer (Fabris and Mocchegiani, 1995).
However, the recent discovery that zinc induces mitogenesis
(Cunningham-Rundles et al, 1990) must not be discounted.
However, recent “in vitro” studies found no mitogenic role of zinc
(physiological dose) on lymphoblastoid cells (Mocchegiani et al,
1994).
Interestingly, “in vitro” zinc (physiological or up-physiological
dose) induces increases in IL-2 production in the supernatants
from PBMCs of cancer patients, despite the fact that intracellular
zinc content of PBMCs is not different between cancer patients
and healthy control subjects (E. Mocchegiani, unpublished obser-
vation). This suggests that exogenous zinc is necessary for good
IL-2 production by lymphocytes of cancer patients, as suggested
previously for aging people (Tanaka et al, 1990). “In vitro” zinc
(0.25 mM) induces a decrease in IL-2 production from PBMCs of
adult healthy humans (Driessen et al, 1994). In agreement with
this last study, we observed a decrease in IL-2 production from
PBMCs of healthy control subjects at zinc concentrations of 10
mM. These findings may confirm a toxic role for zinc in immune
functions at up-physiological or pharmacological doses in healthy
subjects (Chandra, 1984), but, in contrast they suggest the impor-
tance of low zinc bioavailability in impaired immune efficiency in
cervical carcinoma.
The mechanism(s) by which “in vitro” zinc affects immune cell
production of IL-2 could be a direct effect on T-cells by means of
a receptor–MHC complex (Miller and Strittmatter, 1992) or by
means of membrane protein kinase C (PKC) (Csermely et al,
1988). Alternatively, indirect mechanisms mediated macrophage-
produced IL-12, which, in turn, induces Th 1 cells to produce IL-2
(Trinchieri and Scott 1994) may be involved. In any case, zinc
increases IL-2 production from PBMCs of cancer patients,
providing a further rationale for physiological zinc treatment in
cervical carcinoma.
In conclusion, the central (thymic endocrine activity) and
peripheral immune defects (NK and IL-2) might be due to
increased a2-macroglobulin in cervical carcinoma. Whether the
defect of NK activity is due to a low free quota of zinc or to
reduced thymulin activity remains to be clearly established.
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